Drug Patents owned by Supernus Pharms

1. Drug name - OXTELLAR XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10220042 SUPERNUS PHARMS Modified release preparations containing oxcarbazepine and derivatives thereof Apr, 2027

(4 years from now)

US9119791 SUPERNUS PHARMS Modified release preparations containing oxcarbazepine and derivatives thereof Apr, 2027

(4 years from now)

US7910131 SUPERNUS PHARMS Method of treating seizures using modified release formulations of oxcarbazepine Apr, 2027

(4 years from now)

US9855278 SUPERNUS PHARMS Modified release preparations containing oxcarbazepine and derivatives thereof Apr, 2027

(4 years from now)

US11166960 SUPERNUS PHARMS Modified release preparations containing oxcarbazepine and derivatives thereof Apr, 2027

(4 years from now)

US8821930 SUPERNUS PHARMS Modified release preparations containing oxcarbazepine and derivatives thereof Apr, 2027

(4 years from now)

US9351975 SUPERNUS PHARMS Modified release preparations containing oxcarbazepine and derivatives thereof Apr, 2027

(4 years from now)

US7722898 SUPERNUS PHARMS Modified-release preparations containing oxcarbazepine and derivatives thereof Apr, 2027

(4 years from now)

US8617600 SUPERNUS PHARMS Modified release preparations containing oxcarbazepine and derivatives thereof Apr, 2027

(4 years from now)

US9370525 SUPERNUS PHARMS Modified release preparations containing oxcarbazepine and derivatives thereof Apr, 2027

(4 years from now)

Drugs and Companies using OXCARBAZEPINE ingredient

Treatment: Treatment of partial-onset seizures

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
150MG TABLET, EXTENDED RELEASE;ORAL Prescription
300MG TABLET, EXTENDED RELEASE;ORAL Prescription
600MG TABLET, EXTENDED RELEASE;ORAL Prescription

2. Drug name - QELBREE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9358204 SUPERNUS PHARMS Formulations of viloxazine Feb, 2033

(10 years from now)

US9662338 SUPERNUS PHARMS Formulations of viloxazine Feb, 2033

(10 years from now)

US9603853 SUPERNUS PHARMS Formulations of viloxazine Feb, 2033

(10 years from now)

Drugs and Companies using VILOXAZINE HYDROCHLORIDE ingredient

Treatment: For the treatment of attention deficit hyperactivity disorder (adhd)

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 100MG BASE CAPSULE, EXTENDED RELEASE;ORAL Prescription
EQ 150MG BASE CAPSULE, EXTENDED RELEASE;ORAL Prescription
EQ 200MG BASE CAPSULE, EXTENDED RELEASE;ORAL Prescription

3. Drug name - TROKENDI XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10314790 SUPERNUS PHARMS Sustained-release formulations of topiramate Nov, 2027

(5 years from now)

US8889191 SUPERNUS PHARMS Sustained-release formulations of topiramate Nov, 2027

(5 years from now)

US9549940 SUPERNUS PHARMS Sustained-release formulations of topiramate Nov, 2027

(5 years from now)

US8298580 SUPERNUS PHARMS Sustained-release formulations of topiramate Nov, 2027

(5 years from now)

US8877248 SUPERNUS PHARMS Sustained-release formulations of topiramate Nov, 2027

(5 years from now)

US9555004 SUPERNUS PHARMS Sustained-release formulations of topiramate Nov, 2027

(5 years from now)

US9622983 SUPERNUS PHARMS Sustained-release formulations of topiramate Nov, 2027

(5 years from now)

US8663683 SUPERNUS PHARMS Sustained-release formulations of topiramate Nov, 2027

(5 years from now)

US8992989 SUPERNUS PHARMS Sustained-release formulations of topiramate Nov, 2027

(5 years from now)

US8298576 SUPERNUS PHARMS Sustained-release formulations of topiramate Apr, 2028

(5 years from now)

Drugs and Companies using TOPIRAMATE ingredient

Treatment: Use of trokendi xr for the treatment of epilepsy; use of trokendi xr for prophylactic treatment of migraine; Treatment of epilepsy; use of trokendi xr for prophylactic treatment of migraine; Use of trokendi xr for prophylactic treatment of migraine; use of trokendi xr for the treatment of epilepsy; Use of trokendi xr for prophylactic treatment of migraine; treatment of epilepsy

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
25MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
50MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
100MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
200MG CAPSULE, EXTENDED RELEASE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.